Nevirapine Prolonged Release Once-Daily Formulation Available in the UK
Following the approval in Europe last year of a prolonged release (PR) formulation of nevirapine (called extended release/XR in the US), this 400 mg once-daily tablet is now available in the UK.
The lead in dose of 200 mg once daily (using the original formulation) is still required, with the same caution not to increase to the 400 mg daily dose if the patient shows rash at the end of these 14 days.
The daily price of nevirapine PR has been price matched to the price of the 200 mg formulation.
Links to external websites are current at time of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)